ArticleInfection and drug resistance2021
Emergence of
Article in Infection and drug resistance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Prevalence and clonal diversity of carbapenem-resistant Klebsiella pneumoniae causing neonatal infections: A systematic review of 128 articles across 30 countries.PLoS medicine · 2023Pooled it
- Targeting KPC-ProducingMicroorganisms · 2026Article
- Emergence and dissemination of extensively drug-resistant ST307Microbial genomics · 2026Article
- Convergence of multidrug resistance and efflux-mediated biocide tolerance in klebsiella pneumoniae ST307: implications for nosocomial infection control in Iranian hospitals.BMC infectious diseases · 2025Article
- Report of High-Risk Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Retrospective analysis of molecular characteristics, risk factors, and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections.BMC microbiology · 2024Observational
- Outbreak of NDM-5-producingmSystems · 2024Article
- Phenotypic and genomic characteristics of clinical IMP-producing Klebsiella spp. Isolates in China.Communications medicine · 2024Article
- Molecular characteristics and evaluation of the phenotypic detection of carbapenemases amongFrontiers in cellular and infection microbiology · 2024Article
- Molecular Screening of Carbapenem-ResistantJournal of clinical medicine · 2023Article
- Antimicrobial Resistance Patterns, Sequence Types, Virulence and Carbapenemase Genes of Carbapenem-ResistantInfection and drug resistance · 2023Article
- Resistance Phenotype and Molecular Epidemiology of Carbapenem-ResistantInfection and drug resistance · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimWe investigated the clonal diversity of carbapenemase-producing
methodsFrom January 2014 to December 2018, a total number of 36 unique carbapenemase-producing clinical isolates of
resultsThe isolates showed resistance to ceftazidime, ertapenem, ampicillin, cefazolin, ceftriaxone, cefotetan, ticarcillin, cefaclor, cefpodoxime, azlocillin, cefcapene, mezlocillin and ampicillin-sulbactam. Of the 36
conclusionThis study reports on the occurrence and spread of carbapenemase and extended-spectrum β-lactamase encoding genes co-existence in sporadic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.